Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 18, 2017 08:00 ET | Source: TESARO, Inc.

The Foundation for Women’s Cancer and TESARO Announce 2nd Year of Partnership Supporting the National Race to End Women’s Cancer

CHICAGO and WALTHAM, Mass., Oct. 18, 2017 (GLOBE NEWSWIRE) -- The Foundation for Women’s Cancer (FWC), the official foundation of the Society of Gynecologic Oncology, and TESARO, Inc. (NASDAQ:TSRO),...
September 28, 2017 16:30 ET | Source: TESARO, Inc.

TESARO Expands Our Way Forward Program for the Ovarian Cancer Community and Partners With Olympic Gymnast Shannon Miller

WALTHAM, Mass., Sept. 28, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, announced today the availability of a number of new support resources...
September 15, 2017 07:45 ET | Source: TESARO, Inc.

TESARO Receives Positive CHMP Opinion for ZEJULA®

ZUG, Switzerland, Sept. 15, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the European Medicines Agency’s (EMA) Committee...
September 11, 2017 08:00 ET | Source: TESARO, Inc.

TESARO Summarizes ZEJULA and TSR-042 Data Presented at the 2017 ESMO Annual Meeting

MADRID, Spain, Sept. 11, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today provided a summary of ZEJULA and TSR-042, an anti-PD-1 antibody,...
August 25, 2017 08:01 ET | Source: TESARO, Inc.

TESARO Announces Nine Data Presentations at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting

WALTHAM, Mass., Aug. 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that data from nine abstracts will be presented at the...
August 23, 2017 16:15 ET | Source: TESARO, Inc.

TESARO Announces Participation at Four Investor Conferences

WALTHAM, Mass., Aug. 23, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in four upcoming investor...
August 08, 2017 16:05 ET | Source: TESARO, Inc.

TESARO Announces Second-Quarter 2017 Operating Results

ZEJULA is the most prescribed PARP inhibitor in U.S.; Q2 net sales totaled $26 million in first quarter of availabilityRecently opened European niraparib EAP has enrolled 200 patientsVARUBY oral...
July 27, 2017 07:00 ET | Source: TESARO, Inc.

TESARO and Takeda Enter Into Exclusive Licensing Agreement to Develop and Commercialize Novel Cancer Therapy Niraparib in Japan

– Takeda’s Rights Include all Potential Indications for Niraparib in Japan and Rights Excluding Prostate Cancer in South Korea, Taiwan, Russia and Australia – TESARO to Receive $100 Million Upfront...
July 25, 2017 16:15 ET | Source: TESARO, Inc.

TESARO to Announce Second-Quarter 2017 Financial Results on August 8, 2017

WALTHAM, Mass., July 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its second-quarter 2017 financial results on Tuesday, August 8, 2017, after the close of the U.S. financial...
June 29, 2017 09:00 ET | Source: TESARO, Inc.

TESARO Joins OCRFA as Presenting Sponsor of the 2017 Ovarian Cancer National Conference

WALTHAM, Mass., June 29, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to support the Ovarian Cancer Research Fund Alliance (OCRFA) as...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right